Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alliance Pharmaceutical Corp.

www.allp.com

Latest From Alliance Pharmaceutical Corp.

BeneChill Inc.

Lowering brain temperature protects cerebral tissue from ischemic damage, but any delay in inducing hypothermia compromises patient outcomes. BeneChill Inc. noninvasively delivers PFCs to the nose, and the resulting rapid heat exchange selectively cools the brain. The company will design a device for in-hospital use, as well as a version that can be used by first responders in the field.
Medical Device Platform Technologies

Artificial Blood: Finding the Formula for Approval

Despite decades of effort and more than $1 billion dollars invested in commercial blood substitute R&D, no products are approved for use in the US. Can next-generation companies succeed where so many others have failed?
BioPharmaceutical

Millennium: Leaving Europe to Partners

When it comes to Europe, the biotech industry is increasingly saying "no." The latest refusenik: Millennium Pharmaceuticals Inc. That's because Schering-Plough Corp., beset by a host of management and competitive problems, had seen European sales of Millennium's eptifibatide (Integrilin) weaken and decline-and they had never been strong. Merck & Co. Inc.'s tirofiban (Aggrastat), a weak number three in the IIb/IIIa inhibitor US market, had nearly twice Integrilin's sales in Europe; Johnson & Johnson's abciximab (Reopro) had about ten times Integrilin's sales. Millennium re-acquired the European rights and then immediately sold them again, this time to GlaxoSmithKline PLC
Europe

Amersham's Push for High-Value Diagnostics

Amersham Health is applying Big Pharma marketing and R&D strategies to the traditionally stodgy, highly price-sensitive field of diagnostic imaging contrast agents. It has been far more aggressive than competitors in working to make innovation the basis of competition. But some analysts question whether the company can maintain near-to-mid-term growth as it awaits results of its risky, long-term effort in molecular imaging.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alliance Pharmaceutical Corp.
  • Senior Management
  • Duane J Roth, Chmn. & CEO
    Timothy T Hart, VP, CFO
    Jack DeFranco, Pres. & COO
    Jack B DeFranco, Pres. & COO
    Howard Dittrich, MD, SVP, Clinical Research
  • Contact Info
  • Alliance Pharmaceutical Corp.
    Phone: (858) 410-5200
    6175 Lusk Blvd.
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register